Loading
Most people who come through a transplant or CAR-T report, years later, a quality of life close to that of people who never had one. Underneath that, a substantial minority live with fatigue, anxiety, low mood or trouble concentrating, and the strongest predictor is having had anxiety or depression before treatment, which is treatable.
The review of late effects after blood and marrow transplantation states that transplant survivors suffer significant late effects that adversely affect morbidity, mortality, working status and quality of life, and lists neuropsychological effects alongside the organ complications. Working status appears in that sentence for a reason: return to work is one of the outcomes most affected and least studied, and it is a reasonable thing to raise with a team that is focused on counts and scans.
The best long-term patient-reported data in cell therapy come from the study of 40 patients one to five years after CD19 CAR-T described on `rejuv-tx-icans-and-neurocognition`. Mean PROMIS scores for global mental health, global physical health, social function, anxiety, depression, fatigue, pain and sleep disturbance were not clinically meaningfully different from the US general population mean. Within that, 47.5 per cent reported at least one cognitive difficulty, clinically meaningful depression or anxiety, 17.5 per cent scored at least a standard deviation below the population mean on global mental health, and 37.5 per cent reported cognitive difficulties. Younger age was associated with worse long-term global mental health, anxiety and depression, and anxiety or depression before treatment predicted the same afterwards. The authors concluded that a significant number of patients would likely benefit from mental health services.
Two things follow. The first is that group averages conceal the distribution, and a reader should not take a reassuring mean as a statement about themselves. The second is that the two strongest predictors identified, pre-existing mood disorder and younger age, point at something that can be acted on before treatment rather than discovered after it.
What affects quality of life most after an allogeneic transplant specifically is chronic graft-versus-host disease, which is why the modified Lee Symptom Scale, a patient-reported instrument, is a key secondary endpoint in the ruxolitinib and axatilimab trials rather than an afterthought. The gap between clinician-scored and patient-reported response in REACH3, 49.7 per cent against 24.2 per cent, is the clearest single illustration in this file that organ scores and how a person feels are different measurements.
What helps. OnCo holds records for the interventions with the best evidence in survivors generally, and they apply here: structured exercise, which is the best-evidenced single thing a survivor can do and is covered on `exercise-prescription-after-cancer`; cognitive behavioural therapy for insomnia and for persistent fatigue; and psycho-oncology services. None of these has been tested specifically in a randomised trial restricted to transplant survivors, which is why no grade is attached to this record; the evidence is borrowed from the wider survivorship literature, and the borrowing is stated rather than hidden.
Two transplant-specific additions. Chronic GvHD symptom burden responds to treating the GvHD, so persistent symptoms are a reason to review whether the GvHD is adequately controlled rather than only to offer symptomatic support. And the practical load of being a transplant survivor, long-term medication, frequent appointments, infection precautions, travel to a specialist centre, is itself a quality-of-life problem that is rarely counted as one; shared care arrangements and a written plan reduce it.
Quality of life after intensive treatment is determined less by the presence of organ damage than by the combination of symptom burden, functional capacity and psychological state, which is why interventions that change none of the underlying pathology, exercise, sleep therapy and psychological treatment, move it most. Pre-treatment psychological state predicts post-treatment state because the underlying vulnerability persists through the illness rather than being created by it.
Query for this technology: (TITLE:"Quality of life after transplant and cell therapy" OR ABSTRACT:"Quality of life after transplant and cell therapy" OR TITLE:"QoL after HSCT" OR ABSTRACT:"QoL after HSCT" OR TITLE:"return to work after transplant" OR ABSTRACT:"return to work after transplant" OR TITLE:"psychosocial outcomes after cell therapy" OR ABSTRACT:"psychosocial outcomes after cell therapy") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Quality of life after transplant and cell therapy, not a curated reading list.
Shares Chronic graft-versus-host disease, Late effects after a stem cell transplant, After a transplant or cell therapy: what to ask for, Allogeneic stem cell transplantation and the tags rejuvenation, survivorship, transplant.
Shares Chronic graft-versus-host disease, Graft-versus-host disease (GVHD) and graft-versus-leukaemia, After a transplant or cell therapy: what to ask for, Allogeneic stem cell transplantation and the tags rejuvenation, survivorship, transplant.
Shares Fertility, growth and what total body irradiation costs, Late effects after a stem cell transplant, After a transplant or cell therapy: what to ask for, The exercise prescription after cancer: the dose the guidelines state and the tags rejuvenation, survivorship, transplant.
Shares Chronic graft-versus-host disease, Graft-versus-host disease (GVHD) and graft-versus-leukaemia, After a transplant or cell therapy: what to ask for, Quality of life and the tags rejuvenation, survivorship, transplant.
Shares Chronic graft-versus-host disease, Graft-versus-host disease (GVHD) and graft-versus-leukaemia, After a transplant or cell therapy: what to ask for, Allogeneic stem cell transplantation and the tags rejuvenation, survivorship, transplant.
Shares Fatigue after cancer treatment: what actually works, The exercise prescription after cancer: the dose the guidelines state, Quality of life, Survivorship care and late-effects surveillance and the tags rejuvenation, survivorship, psychosocial.
Shares Chronic graft-versus-host disease, Graft-versus-host disease (GVHD) and graft-versus-leukaemia, After a transplant or cell therapy: what to ask for, Allogeneic stem cell transplantation and the tags rejuvenation, survivorship, transplant.
Shares AlloCare: a stepped-care late-effects service after allogeneic transplant, Late effects after a stem cell transplant, After a transplant or cell therapy: what to ask for, Allogeneic stem cell transplantation and the tags rejuvenation, survivorship, transplant.